Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $5 to $28, according to analysts polled by Capital IQ. (MT...
...
Axcella Health (AXLA) has an average outperform rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires...
Axcella Health (AXLA) has an average outperform rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires...
| Address | 840 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.857.320.2200 |
| Number of Employees | 49 |
| Recent SEC Filing | 01/20/2022 4 |
| President, Chief Executive Officer & Director | William R. Hinshaw |
| Chief Scientific Officer, Senior VP-R&D | Tony Tramontin |
| Chief Medical Officer & Senior Vice President | Margaret Koziel |
| President-Research & Development | Alison Schecter |
| Price Open | $1.79 |
| Previous Close | $1.78 |
| 52 Week Range | $1.45 - 6.84 |
| Market Capitalization | $62.7 M |
| Shares Outstanding | 38.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/16/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.64 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -112.24% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
